Indian vaccine for pneumonia can protect young children from severe symptoms of corona
Serum Institute of India (SII), the world's largest vaccine manufacturer, has launched India's first indigenous vaccine Nimosil to protect against pneumococcal disease. The company reported that pneumonia is one of the severe symptoms of corona. Currently, the corona vaccines being made worldwide, their tests have not been done on young children. In such a situation, the vaccine that protects against pneumococcal can also protect young children from severe symptoms of corona.
Pneumococcal infection is caused by bacteria. It is included in the larger arms of pneumonia. Dr. Rajeev Dhere, executive director of SII, said that we can expect that the pneumococcal vaccine will play an important role in preventing severe pneumonia in children. Anyway, the vaccine being made for Corona at this time is not for children. The Nimosil vaccine is thus an expectation for children.
The vaccine will provide long-term protection to children.
SII has developed the Nimosil vaccine in collaboration with PATH and the Bill & Melinda Gates Foundation. This is a big success in providing vaccines easily in countries like India where people have low income. The new vaccine will give children long-term effective protection against pneumococcal diseases. Union Health Minister Harsh Vardhan, who was present during the launch of the vaccine, said that this is a big achievement for the public healthcare of the country.
The risk of pneumococcal children under the age of 5 years,
SII CEO Adar Poonawala said, because of pneumococcal disease, children under the age of five continue to be at risk worldwide. In 2018, 67 thousand 800 children died under the age of 5 due to pneumococcal. This vaccine will be effective in saving such children.
KoviShield will also get approval soon
SII CEO Adar Poonawalla claims that AstraZeneca and Oxford University vaccine KoviShield for Corona will get emergency approval in the early weeks of January in the country. Currently, 4-5 crore vaccine stocks are ready. The company will provide 100 million vaccines by July -21.
On the question of KoviShield being effective, Poonawalla said, "There is no doubt about KoviShield. The CEO of AstraZeneca has also clarified that this vaccine is 100?fective. So, we should wait for the decision of the drug regulator." Hopefully our vaccine will get emergency approval in January. "